Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
ß-lactam antibiotics	481.76M	-						628.44M	509.57M	455.63M
ß-lactam antibiotics Growth	-	-						23.33%	11.84%	-
Anticholinergics and Synthetic Antispasmodics	197.10M	-						92.52M	89.91M	94.60M
Anticholinergics and Synthetic Antispasmodics Growth	-	-						2.91%	-4.96%	-
Quinolones Antibiotics	108.30M	-						55.41M	77.88M	58.82M
Quinolones Antibiotics Growth	-	-						-28.86%	32.41%	-
Antifungal drugs for skin	71.61M	-						52.44M	30.13M	23.04M
Antifungal drugs for skin Growth	-	-						74.04%	30.76%	-
Other Products	47.43M	-						19.13M	12.97M	48.63M
Other Products Growth	-	-						47.45%	-73.32%	-
Total	906.19M	-						847.94M	720.47M	680.72M
Total Growth	-	-						17.69%	5.84%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	700.77M	-						698.99M	618.57M	543.29M
China Growth	-	-						13.00%	13.86%	-
Overseas	205.42M	-						148.96M	101.90M	137.43M
Overseas Growth	-	-						46.18%	-25.85%	-
Total	906.19M	-						847.94M	720.47M	680.72M
Total Growth	-	-						17.69%	5.84%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 15, 2026

Data Sources Report a data error